Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation

Grants

Funding Acknowledgements

This study was sponsored by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis and also funded all costs associated with the development and the publishing of the present manuscript. The authors had full access to the data and the corresponding author was responsible for submission of the publication.